Alisha Wainwright

Wow, Abiola brought up so many good points.

I'm wondering how big of a part is advocacy in the women trials?

So the women trial raised a lot of questions from how to administer the drug to how to improve accessibility.

But there are also other big questions that inspired new trials.

So can you tell me a bit about the women to trial and what were some of the questions you were trying to answer with that?

Makes sense.

Hypothesis, yeah.

To be fair, you're a health care provider.

You want to find a solution to a problem and save as many lives.

You think if it works in this way, why wouldn't it work in this other way?

I support and validate your assumption.

So then how did you get from Women Trial 2 to Women Trial 3?

Oh, that's so interesting.

Okay.

So it's women three is almost before you get to the point where you like way before.

So that's even though the results from trial two were not what you expected, it created a whole slide.

store of new questions that could potentially still help in the end, which I always love.

I know it's not what you might want to hear, but I always love when you get results that aren't what you expect.

I do think those results are still worth publishing because just because you didn't get the answer you wanted, it doesn't mean you're

It doesn't propel you forward with new questions and new ideas so that perhaps the following trials can have even more impact.